All the way up! The Innovative Drugs Sector in Hong Kong stocks surged collectively, with multiple stocks doubling this year. Who is reshaping the valuation?

The rise in the Hong Kong stock market's Innovative Drugs Sector continues. Market analysts point out that this wave of Innovative Drugs momentum benefits from a combination of factors including market sentiment, policy, and the realization of the companies' own commercial value.

Securities TimesMar 13 09:50

What does AI pharmaceuticals still lack before a market explosion? | Focus

① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.

cls.cnJan 20 08:34

C HEALTH GP (08225): Wang Dajun resigned as a non-executive Director.

C HEALTH GP (08225) announced that due to the adjustment of the group's organizational structure and Mr. Wang Dajun's personal...

Zhitong FinanceJan 17 22:38

C HEALTH GP: INTERIM REPORT FOR THE SIX MONTHS ENDED 30 JUNE 2024

HKEXSep 26, 2024 12:43 · Announcements

C Health GP (08225.HK): Appointed Guo Ruimeng as executive director and chief artificial intelligence officer.

On September 11th, Guolonghui announced that Dr. Song has resigned from his position as an executive director and supervisory director of c health gp due to the retirement of Song Xuemei, and his resignation will be effective from September 11th, 2024. In addition, Guo Ruimeng has been appointed as an executive director and the Chief Artificial Intelligence Officer (CAIO) of the company, and the appointment will be effective from September 11th, 2024.

Gelonghui FinanceSep 11, 2024 16:34

C HEALTH GP: Supplementary Announcement on Financial Assistance

HKEXAug 29, 2024 22:01 · Announcements